Dr REDDY LAB.

FACT FILE.
FOUNDER: ANJI
REDDY.
( Dr. Reddy's Laboratories Ltd., trading as Dr.
Reddy's, founded in 1984 by Dr.K.Anji Reddy has
become Indias second biggest pharmaceutical
company.)
DISTINCTION: SECOND
PRIMARY PRODUCT:1.

NUMBER OF
EMPLOYEE:8225
MAJOR COMPETITORS: Ranbaxy Lab.
Sun Pharmaceutical.
Teva Pharmaceutical.
CHAIRMAN: Anji Reddy.
CEO AND PRESIDENT: G V PRASAD
HEAD QUARTERS:Hyderabad,Andhra
Pradesh,INDIA.
YEAR FOUNDED:1984
WEBSITE:www.drreddys.com

HISTORY:
1984-Dr Anji Reddy establishes Dr. Reddy's Laboratories with an initial
capital outlay of Rs.25 lakhs.

1986 - Dr. Reddy’s listed on Bombay Stock Exchange (BSE).

Dr. Reddy’s enters international markets.

1987-Obtains its first USFDA approval for Ibuprofen API.

Starts its formulations operations

1988-Acquires Benzex Laboratories Pvt. Limited to expand its

Bulk Actives business.

1990- Dr. Reddy’s, for the first time in India, exports Norfloxacin
and Ciprofloxacin to Europe and Far east.

1993-Dr. Reddy's Research Foundation established.

The company's drug discovery programme starts.

1995-Sets up of a Joint Venture in Russia.

1999-Acquisition of American Remedies Limited, a
pharmaceutical company based in India.

2000-Dr. Reddy's Laboratories becomes India's third largest

pharmaceutical company with the merger of Cheminor Drugs
Limited, a group company.
2001-Becomes the first Asia Pacific pharmaceutical company,
outside Japan, to list on the New York Stock Exchange.
Launches its first generic product, Ranitidine, in the US market.

2002-Conducts its first overseas acquisition – BMS Laboratories

Limited and Meridian Healthcare in UK.

2006-
Dr. Reddy's obtains its second 180-day marketing exclusivity for a
generic drug in the US market with the launch of Ondenesetron
Hydrochloride Tablets.
Acquires betapharm- the fourth-largest generics company in
Germany for a total enterprise value of € 480 million.
2007-Becomes No.1 pharmaceutical company in India in
turnover and profitability.

2009-
Announces strategic alliance with GlaxoSmithKline plc to develop
and market select products across emerging markets outside
India.

2006-
Dr. Reddy's obtains its second 180-day marketing exclusivity for a
generic drug in the US market with the launch of Ondenesetron
Hydrochloride Tablets.
Acquires betapharm- the fourth-largest generics company in
Germany for a total enterprise value of € 480 million.
2007-Becomes No.1 pharmaceutical company in India in
turnover and profitability.

2009-
Announces strategic alliance with GlaxoSmithKline plc to develop
and market select products across emerging markets outside
India.
GLOBAL GENERIC
Branded Generics
Branded Generics portfolio offers over 200 products in
the major therapeutic areas of gastro-intestinal,
cardiovascular, pain management, oncology, anti-
infectives, paediatrics and dermatology. Brands like
Omez, Ciprolet, Nise, Enam, Ketorol, Exifine and
Cetrine enjoy leadership positions in several key
markets, including India, Romania, Venezuela, Russia.

Deep customer relationships, quality medicines and

consistently delivered promise make Dr REDDY trusted
brand across the world.

Unbranded-Generics
The unbranded generics space,have capitalized on every
opportunity to bring our high-quality products to more people
around the world. A synchronized supply chain that leverages
strong product development capabilities, state-of-the-art
manufacturing and vertical integration with our own APIs has
created a creditable track record of successful “Day 1”
launches, with significant market shares in all our key markets.
The transparent and strong relationships with pharmacy
chains, insurance funds and other distributor networks help us
deliver upon there promise to customers and patients globally.

There generics offerings deliver quality at cost-effective prices

in the highly regulated markets of the United States, UK and
Germany. In the US, they rank among the top 12 generic
companies, with 34 product families being marketed and a
large pipeline pending approval. In the UK, they have more
than 30 products in the market. There acquisition of
betapharm, Germany's 5th largest generics company, further
consolidated there presence in the European Union (EU), with
145 products in the market.

KEY PRODUCT.
TOP ACTIVE PHARMACEUTICAL INGREDIENT.

• Ciprofloxacin Hydrochloride.
• Ramipril
• Terbinafine HCL
• Ibuprofen
• Sertaline Hydrochloride
• Ranitidine HCL
• Naproxen Sodium.
 • Naproxen
• Losartan Potassium
Atrovastatin
• Montelukast
• .

TOP 10 BRANDS IN INDIA.

 Omez
 Nise
 Stamlo
 Razo
 Reclimet
 Clamp
 Mintop
 Stamlo Beta
 Enam
 Atocor


FOCUS THERAPEUTIC AREAS.

BACTERIAL INFECTION.
The incidence of hospital acquired infections is growing as drug-
resistant bacteria are becoming more difficult to treat. There are
significant challenges in adequately treating infections caused by
multi-drug resistant pathogens such as staphylococcus aureas,
pseudomonas aeruginosa, and acinetobacter baumannii. The
resultant infections are often serious and life-threatening.So,Dr
REDDYS LAB is working to identify new approaches to treating
these infections with products that have improved efficacy and
tolerability profiles.

METABOLIC DISORDER.
Cardiovascular Disease is one of the leading causes of death
globally. Many patients suffering from CVD are also afflicted with
insulin resistance, type 2 diabetes, dyslipidemia, and obesity.
While there are several treatment options for a few of these
conditions, a need persists for effective and safe therapies that
address insulin resistance, obesity, low HDL cholesterol and
atherosclerosis. So Dr REDDY LAB have several programs
targeting one or more of these disease condition.
PAIN /INFLAMMATION.
The prevalence of chronic and acute pain is growing steadily
as the population ages and diagnosis rates improve. Although
there are a number of medications to treat chronic and acute
pain, new treatments that are both safe and tolerable remain
essential. Dr REDDY LAB are developing products with
improved efficacy and side effect profiles in several areas of
acute and chronic pain.

PRODUCTS OF DR. REDDY’S LAB. -

Active Pharmaceutical Ingredients (API): Dr. Reddy's
Laboratories product list span 24 major chemistries including
stereo-selective synthesis, cryogenics, hydrogenations and
cyanations. It has filed 84 US DMFs, the highest in India and
second highest in the world.
Custom Pharmaceutical Services: Dr. Reddy's executes cost-
effective and time-bound projects for its customers, and provides
them cGMP-compliant products manufactured in FDA-inspected,
ISO-certified facilities.

Generic Dosages: Dr. Reddy's Lab is a leading generic drugs

manufacturer. It is the fourth largest player in Germany after the
acquisition of betapharm. The company has expertise in
customer-specific packaging, compliance packaging, anti-
counterfeit packaging, and has won several awards globally for its
packaging efforts, including the Asia Star, AmeriStar and
WordStar awards.

Branded Dosages: Dr. Reddy's brands such as Omez

(Omeprazole), Nise (Nimesulide), Stamlo (Amlodipine), Ciprolet
(Ciprofloxacin), Enam (Enalapril) and Ketorol (Ketorolac) are
leaders in their category in several countries. Discovery
Research: Dr. Reddy's is actively involved in drug-discovery and
clinical development programs.
Key Brands and Product Pipeline.
DRL markets approximately 160 products in the European Union
and has more than 200 branded formulations available in the rest
of the world. In the United States, DRL sells leading generic drugs
including but not limited to Simvastatin for lowering cholesterol
(brand name Zocor from Merck), Sumatripan AG for migraine
(brand name Imitrex from GlaxoSmithKline) and Oxaprozin for
anti-inflammation (brand name Daypro from Pfizer).

Generic drugs in Germany include Oxycodon and Ibuprofen.

Branded dosages in India include Omez, Razo and Nise and in
Russia, Omez, Ciprolet, Enam and Ketorol.

DRL had 159 abbreviated new drug applications and 351 drug
master files as of March 2009.
Research is underway to develop new chemical entities to treat
metabolic, cardiovascular and respiratory diseases.

The company has eight biopharmaceutical products in its pipeline,

and its differentiated formulations division is in the process of
developing therapies for the treatment of dermatological disorders
through its wholly owned subsidiary Promius Pharma, located in
New Jersey.